Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.34 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.34 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15313628 | 0.96 | KCNH2 (0.93) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL1050138 | 0.96 | KCNH2 (0.93) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL2068565 | 0.95 | KCNH2 (0.91) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL30718393 | 0.95 | KCNH2 (0.91) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL30718360 | 0.95 | KCNH2 (1.00) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL1049907 | 0.95 | KCNH2 (1.00) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL1051285 | 0.94 | KCNH2 (0.89) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL30718374 | 0.94 | KCNH2 (0.88) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL30718395 | 0.94 | KCNH2 (0.88) | KCNH2CYP3A4TUBB4ATUBBTUBA3C | |
| SCHEMBL12783655 | 0.94 | KCNH2 (0.88) | KCNH2CYP3A4TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509439-B2 | Anti-malarial agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-12-30 | — | — | US | claimed |
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | claimed |
| EP-4574143-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | Universität Regensburg (DE) | 2025-06-25 | — | — | EP | claimed |
| EP-3990434-B1 | 1,1'-[1,3-(5-METHOXY)PHENYLENEBIS(METHYLENE)]BIS[4,5-DIPHENYL-1H-IMIDAZOLE] AND SIMILAR COMPOUNDS FOR THE TREATMENT OF MALARIA | UNIV NANYANG TECH (SG) | 2025-06-25 | — | — | EP | claimed |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-19 | — | — | US | claimed |
| EP-4499631-A1 | PYRAZINE AMIDE DERIVATIVES | Novartis AG (CH) | 2025-02-05 | — | — | EP | claimed |
| CN-118766947-A | Methods for treating SARS CoV-2 infection | 吉利德科学公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118662520-A | Methods for treating SARS CoV-2 infection | 吉利德科学公司 | 2024-09-20 | — | — | CN | claimed |
| CN-118591538-A | Pyrazinamide derivatives | 诺华股份有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-114787167-B | Compounds and compositions for the treatment of parasitic diseases | 诺华股份有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-20200171037-A1 | THERAPEUTIC REGIMEN | NOVARTIS AG (CH) | 2020-06-04 | — | — | US | claimed |
| EP-3615030-A1 | THERAPEUTIC REGIMEN OF 2-AMINO-L-(2-(4-FLUOROPHENYL)-3-(4-FLUOROPHENYLAMINO)-8,8-DIMETHYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)ETHANONE AND COMBINATIONS THEREOF | Novartis AG (CH) | 2020-03-04 | — | — | EP | claimed |
| WO-2018198021-A1 | THERAPEUTIC REGIMEN OF 2-AMINO-L-(2-(4-FLUOROPHENYL)-3-(4-FLUOROPHENYLAMINO)-8,8-DIMETHYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)ETHANONE AND COMBINATIONS THEREOF | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | claimed |
| US-20180303837-A1 | THERAPEUTIC REGIMEN | NOVARTIS AG (CH) | 2018-10-25 | — | — | US | claimed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | claimed |
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2013-10-24 | — | — | US | claimed |
| US-8557801-B2 | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (BM) | 2013-10-15 | — | — | US | claimed |
| EP-2451814-A2 | FUSED IMIDAZOLES AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS E.G. MALARIA | IRM LLC (BM) | 2012-05-16 | — | — | EP | claimed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | claimed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171037-A1 | THERAPEUTIC REGIMEN | DHFR, THPO, G6PD | KCNH2 4674/4885CYP3A4 190/4885CYP1A2 458/4885 |
| US-20180303837-A1 | THERAPEUTIC REGIMEN | DHFR, THPO, G6PD | KCNH2 4674/4885CYP3A4 190/4885CYP1A2 458/4885 |
| US-12509439-B2 | Anti-malarial agents | RCC1, PFN1, NHERF1 | KCNH2 1600/4885CYP3A4 333/4885CYP1A2 140/4885 |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | KCNH2 2202/4885CYP3A4 221/4885CYP1A2 121/4885 |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | SIRT5, GLS2, ARG2 | KCNH2 1105/4885CYP3A4 190/4885CYP1A2 24/4885 |
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, ABCB1, FDPS | KCNH2 1679/4885CYP3A4 97/4885CYP1A2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.